Patents Assigned to Biogen MA Inc.
  • Patent number: 10563163
    Abstract: Aspect of the disclosure relate to methods of assessing a bioreactor culture that involve determining a culture parameter of the manufacturing-scale bioreactor culture using a model that relates a Raman spectrum to the culture parameter. Related bioreactor system are also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 18, 2020
    Assignee: Biogen MA Inc.
    Inventors: Brandon Berry, Justin Moretto
  • Publication number: 20200046804
    Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
    Type: Application
    Filed: October 22, 2019
    Publication date: February 13, 2020
    Applicant: Biogen MA Inc.
    Inventor: Aaron DEYKIN
  • Patent number: 10556059
    Abstract: An infusion pump drive and its methods of use are disclosed. In one embodiment, the infusion pump drive may include a transmission component and a spring in line with the transmission component. Displacing the transmission component may compress the spring to apply a force causing fluid to dispense from an associated reservoir. Depending on the particular embodiment, the transmission component may either be displaced continuously or displaced multiple times to dispense fluid from the reservoir.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: February 11, 2020
    Assignee: Biogen MA Inc.
    Inventors: David Cross, Michael Paton
  • Patent number: 10555993
    Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: February 11, 2020
    Assignee: Biogen MA Inc.
    Inventor: Vissia Viglietta
  • Publication number: 20200040342
    Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
    Type: Application
    Filed: July 16, 2019
    Publication date: February 6, 2020
    Applicant: Biogen MA Inc.
    Inventor: Eric E. Swayze
  • Publication number: 20200016072
    Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 16, 2020
    Applicant: Biogen MA Inc.
    Inventor: Matvey E. Lukashev
  • Patent number: 10500254
    Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 10, 2019
    Assignee: BIOGEN MA INC.
    Inventor: Aaron Deykin
  • Publication number: 20190365892
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: June 14, 2019
    Publication date: December 5, 2019
    Applicant: BIOGEN MA INC.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • Patent number: 10494416
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 3, 2019
    Assignees: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Publication number: 20190358190
    Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 28, 2019
    Applicant: Biogen MA Inc.
    Inventors: David Goldman, Katherine Dawson, Ajay Nirula
  • Publication number: 20190359634
    Abstract: Provided are compounds of Formulas (I?), (I), (II?) and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: February 6, 2018
    Publication date: November 28, 2019
    Applicant: BIOGEN MA INC.
    Inventors: Felix Gonzalez Lopez de Turiso, Martin Himmelbauer, Michael J. Luzzio
  • Publication number: 20190359706
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist.
    Type: Application
    Filed: April 23, 2019
    Publication date: November 28, 2019
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky
  • Patent number: 10466251
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: November 5, 2019
    Assignee: BIOGEN MA INC.
    Inventor: Theodore A. Yednock
  • Publication number: 20190330307
    Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
    Type: Application
    Filed: October 19, 2017
    Publication date: October 31, 2019
    Applicant: BIOGEN MA INC.
    Inventors: HQ HAN, Xiaolan ZHOU
  • Publication number: 20190320989
    Abstract: Embodiments related to methods and wearable medical detecting systems for detecting disease states and/or treatment states of a subject are described. In one embodiment, a wearable structure may include one or more radiation detectors use to detect a time varying radiation signal emitted from a labeled compound within a body portion of interest. The radiation signal may be analyzed to determine one or more signal characteristics that may be compared to one or more predetermined standard characteristics associated with known disease and/or treatment states to determine a current disease and/or treatment state of a subject.
    Type: Application
    Filed: November 22, 2017
    Publication date: October 24, 2019
    Applicant: Biogen MA Inc.
    Inventors: Ajay Verma, Elliot Greenblatt, Ira Spool, Seth O. Newburg, Guy M. Danner, Ara N. Knaian, Rachel M. Chaney
  • Patent number: 10444234
    Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: October 15, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
  • Patent number: 10436802
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of SMN protein in a sample of cerebrospinal fluid.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 8, 2019
    Assignee: Biogen MA Inc.
    Inventors: Frank Rigo, Katherine M. Bishop
  • Patent number: 10435467
    Abstract: Methods, compositions and kits comprising an anti-LINGO antibody molecule are described herein useful for detecting and/or treating a CNS demyelinating disease.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: October 8, 2019
    Assignee: Biogen MA Inc.
    Inventors: Diego Cadavid, Sha Mi
  • Patent number: 10420497
    Abstract: This disclosure relates to a device to mechanically and electrically connect with a touch screen computing device, such as a tablet computer. The device can include a platform that can be moved into and out of physical contact with a surface of a touch screen. During engagement with the surface, the moveable platform electrically interacts with the touch screen (e.g., via capacitive coupling) to enable detection by the touch screen of contact members (e.g., pegs) even in the absence of user contact with the pegs.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: September 24, 2019
    Assignees: THE CLEVELAND CLINIC FOUNDATION, BIOGEN MA, INC.
    Inventors: Jay L. Alberts, David D. Schindler, Jane Rhodes, Wendy Gabel, Jim Best
  • Publication number: 20190284281
    Abstract: Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythematosus, and cytokine release syndrome.
    Type: Application
    Filed: April 27, 2017
    Publication date: September 19, 2019
    Applicant: Biogen MA Inc.
    Inventors: Mark R.H. Krebs, David Dai, Shantanu Sule, Dania Rabah, David Martin